As Helicos Navigates Bankruptcy Process, Details Emerge on Disputes with Creditors and Customers | GenomeWeb

Helicos will be able to use cash collateral, at least on an interim basis, to continue funding its operations as it navigates its way through the bankruptcy process and attempts to sell off its intellectual property, according to an order issued last month from the US Bankruptcy Court for the District of Massachusetts Eastern Division.

Helicos filed for Chapter 11 bankruptcy protection last month after the loss of a key IP suit on which it had pinned its hopes for financial recovery. A final hearing on the cash collateral motion is scheduled for Jan. 8, 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.